Exacerbation rate, health status and mortality in COPD--a review of potential interventions

Terence A R Seemungal, John R Hurst, Jadwiga A Wedzicha, Terence A R Seemungal, John R Hurst, Jadwiga A Wedzicha

Abstract

COPD is prevalent in Western society and its incidence is rising in the developing world. Acute exacerbations of COPD, about 50% of which are unreported, lead to deterioration in quality of life and contribute significantly to disease burden. Quality of life deteriorates with time; thus, most of the health burden occurs in more severe disease. COPD severity and frequent and more severe exacerbations are all related to an increased risk of mortality. Inhaled corticosteroids (ICS) have similar effects on quality of life but ICS/long-acting bronchodilator combinations and the long-acting antimuscarinic tiotropium all improve health status and exacerbation rates and are likely to have an effect on mortality but perhaps only with prolonged use. Erythromycin has been shown to decrease the rate of COPD exacerbations. Pulmonary rehabilitation and regular physical activity are indicated in all severities of COPD and improve quality of life. Noninvasive ventilation is associated with improved quality of life. Long-term oxygen therapy improves mortality but only in hypoxic COPD patients. The choice of an inhaler device is a key component of COPD therapy and this requires more attention from physicians than perhaps we are aware of. Disease management programs, characterized as they are by patient centeredness, improve quality of life and decrease hospitalization rates. Most outcomes in COPD can be modified by interventions and these are well tolerated and have acceptable safety profiles.

Keywords: COPD; disease management program; exacerbation; exercise; health burden; inhaled steroids; long-acting antimuscarinic agents; long-acting bronchodilators; macrolide; mortality; pulmonary rehabilitation; safety; tolerability.

Figures

Figure 1
Figure 1
The interaction of safety, tolerability and efficacy.

References

    1. Bonet T. Geneva: Sepultrechretum sive anatomica pructica ex Cadaveribus Morbo denatis, proponens Histoa’s Observations omnium pene humani corporis affectuum, ipsarcomoue Causas recordatis revelans; p. 1679.
    1. Petty TL. The history of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:3–14.
    1. Laennec RTH. A treatise on the diseases of the chest (English translsation for the French). Preface and notes by Forbes J. London T and G Underwood. :1837.
    1. Tiffeneau R, Pinelli AF. Aire circulant et air captif dans l’exploration de la function ventilatrice pulmonaite. Paris Med. 1947;133:624–628.
    1. Fletcher CM, Jones NL, Burrows B, Niden AH. American emphysema and British bronchitis: A standardized comparative study. Am Rev Resp Dis. 1964;90:1–13.
    1. Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airway obstruction: a clinopathological study of patients in London and Chicago. Lancet. 1966;1:830–835.
    1. Jones NL, Burrows B, Fletcher CM. Serial studies of 100 patients with chronic airway obstruction in London and Chicago. Thorax. 1967;22:327–335.
    1. Briscoe WA, Nash ES. The slow space in chronic obstructive pulmonary diseases. Ann N Y Acad Sci. 1965;121:706–722.
    1. Sukumalchantra Y, Williams MH. Serial studies of pulmonary function in patients with chronic obstructive pulmonary disease. Am J Med. 1965;39:941–945.
    1. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 1968;278:1355–1360.
    1. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airwayys and pulmonaryfunction tests. N Engl J Med. 1978;298:1277–1281.
    1. Petty TL, Silvers GW, Stanford RE. Small airway disease is associated with elastic recoil changes in excised human lungs. Am Rev Respir Dis. 1984;130:42–45.
    1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) Am J Respir Crit Care Med. 1995;152:S77–S120.
    1. ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1995;8:1398–1420.
    1. BTS Guidelines. For the management of chronic obstructive pulmonary disease. BMJ. 1997;52:S2–S15.
    1. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115–122.
    1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645–1648.
    1. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986;133:14–20.
    1. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;16:1539–1541.
    1. Anthonisen NR. Smoking, lung function, and mortality. Thorax. 2000;55:729–734.
    1. Hole DJ, Watt GCM, DaveySmith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women:findings from the Renfew and Paisley prospective population study. BMJ. 1996;313:711–715.
    1. Thomason MJ, Strachan DP. Which spirometric indices best predict death from chronic obstructive pulmonary disease. Thorax. 2000;55:785–788.
    1. AïtKhaled N, Enarson DA, Ottmani S, El Sony A, Eltigani M, Sepulveda R. Chronic airflow limitation in developing countries: burden and priorities. Int J Chron Obstruct Pulmon Dis. 2007;2:141–150.
    1. Buist AS, McBurnie MA, Vollmer WM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–750.
    1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 19902020: Global Burden of Disease Study. Lancet. 1997;349:1498–1504.
    1. Seemungal T, Harrinarine R, Rios M, et al. Obstructive Lung Disease in Acute Medical Patients. West Indian Med J. 2008;57:71–74.
    1. Liu S, Zhou Y, Wang X, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax. 2007;62:83–89.
    1. Driscoll T, Nelson DI, Steenland K, et al. The global burden of non-malignant respiratory disease due to occupational airborne exposures. Am J Ind Med. 2005;48:432–445.
    1. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology. 2003;8:504–508.
    1. Jindal SK, Aggarwal AN, Gupta D. A review of population studies from India to estimate national burden of chronic obstructive pulmonary disease and its association with smoking. Indian J Chest Dis Allied Sci. 2001;43:139–147.
    1. Groenewald P, Vos T, Norman R, et al. 2000S Afr Med J 2007 7(8 Pt 2)674–681.
    1. ChanYeung M, AïtKhaled N, White N, Ip MS, Tan WC. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis. 2004;8:21–24.
    1. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Ruttenvan Mölken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med. 2001;164:590–596.
    1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic Obstructive Pulmonary Disease Surveillance – United States, 19712000. MMWR. 2002;51(S6):116.
    1. Varkey AB. Chronic obstructive pulmonary disease in women: exploring gender differences. Curr Opin Pulm Med. 2004;10:98–103.
    1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and metaanalysis. Eur Respir J. 2006;28:523–532.
    1. Soriano JB, Maier W, Egger P, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax. 2000;55:789–794.
    1. Schirnhofer L, Lamprecht B, Vollmer WM, et al. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) study. Chest. 2007;131:29–36.
    1. Han MK, Postma D, Mannino DM, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med. 2007;2007;176(12):1179–1184.
    1. Mannino DM, Buisto AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773.
    1. Tager I, Speizer FE. Role of infection in chronic bronchitis. N Engl J Med. 1975;292(11):563–571.
    1. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with Asthma. Thorax. 1998;53:129–136.
    1. Monto AS, Higgins MW, Ross HW. The Tecumseh study of respiratory illness. Acute infection in chronic respiratory disease and comparison groups. Am Rev Infect Dis. 1975;11:27–36.
    1. Kanner RE, Renzetti AD, Jr, Klauber MR, Smith CB, Golden CA. Variables associated with changes in spirometry in patients with obstructive lung diseases. Am J Med. 1979;67:44–50.
    1. Anthonisen NR, Manfreda J, Warren CP, Heshford EW, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.
    1. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1618.
    1. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, INSPIRE Investigators The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.
    1. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422.
    1. Johnston AK, Mannino DM. Epidemiology of COPD exacerbations. In: Wedzicha JA, Martinez F, editors. Exacerbations Of Chronic Obstructive Pulmonary Disease (COPD) New York: Informa Healthcare; 2008.
    1. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303.
    1. Seemungal T, Stockley R, Calverley P, Hagan G, Wedzicha JA. Investigating New Standards for Prophylaxis In Reduction of Exacerbations The INSPIRE Study Methodology. COPD. 2007;4:177–183.
    1. Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Early therapy improves outcomes of exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2004;169:1298–1303.
    1. Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177:396–401.
    1. Vijaysaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008;133:34–41.
    1. McCormick A, Fleming D, Charlton J.Morbidity statistics from general practice: Fourth national study 19912: Office of Population Census and LondonSurveys; 1995
    1. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941–1947.
    1. Goldacre MJ, Ferguson JA. Inpatient workload in medical specialities: demographic studies and time trends from linked statistics. Q J Med. 1995;88:649–660.
    1. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease:a randomised controlled trial. Lancet. 1999;353:1819–1823.
    1. Foreman MG, DeMeo DL, Hersh CP, Reilly JJ, Silverman EK. Clinical determinants of exacerbations in severe, earlyonset COPD. Eur Respir J. 2007;30(6):1124–1130.
    1. Patel IS, Seemungal TAR, Wilks M, Lloyd Owen S, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax. 2002;57:759–764.
    1. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120.
    1. Seemungal TAR, HarperOwen R, Bhowmik A, et al. Respiratory viruses and symptoms, inflammatory markers in acute exacerbations of COPD. Am J Respir Crit Care Med. 2001:1618–1623.
    1. Spencer S, Calverley PMA, Burge PS, Jones PW, on behalf of the Isolde Study Group Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:122–128.
    1. Kanner RE, Anthonisen NR, Connett J, for the Lung Health Study Lower respiratory illnesses promote FEV1 decline in smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med. 2001;164:358–364.
    1. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852.
    1. SolerCataluna JJ, MartínezGarcía MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931.
    1. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med. 1999;93:161–166.
    1. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31:927–933.
    1. Keene ON, Calverley PMA, Jones PW, Vestbo J, Anderson JA. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J. 2008;32:17–24.
    1. Suissa S. Exacerbations and intent-to-treat analyses in randomised trials. Eur Respir J. 2008;32:1117–1118.
    1. Jones PW, Quirk FH, Baveystock CM. The St. Georges Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25–31.
    1. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56:880–887.
    1. Okubadejo AA, Jones PW, Wedzicha JA. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Thorax. 1996;51:44–47.
    1. Schrier A, Dekker FW, Kaptein AA, Dijkman JH. Quality of life in elderly patients with chronic nonspecific lung disease seen in family practice. Chest. 1990;98:894–899.
    1. Jones PW, Bosh TK. Quality of life changes in COPD patients with Salmeterol. Am J Respir Crit Care Med. 1997;155:1283–1289.
    1. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33:190–201.
    1. Intermittent Positive Pressure Breathing Trial Group (IPPB Trial Group). Intermittent positive pressure breathing of COPD. Ann Intern Med. 1983;99:612–620.
    1. MeechamJones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnoeic COPD. Am J Respir Crit Care Med. 1995;152:538–544.
    1. Garrod R, Mikelsons C, Paul EA, Wedzicha JA.Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease Am J Respir Crit Care Med 2000162(4 Pt 1)133–541.
    1. Wijkstra PJ, Altena RV, Kraan J, Otten V, Postme DS, Koeter GH. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Resp J. 1994;7:269–273.
    1. Goldstein RS, Gort EDH, Stubbing D, Avendano MA, Guyatt GH. Randomised controlled trial of respiratory rehabilitation. Lancet. 1994;344:1394–1397.
    1. Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW. Randomised controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J. 1998;12:363–369.
    1. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital readmission in patients with chronic obstructive pulmonary disease. Thorax. 1997;52:67–71.
    1. Spencer S, Jones PW, for the GLOBE Study Group Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589–593.
    1. Guyatt GH, Berman LB, Towensend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773–778.
    1. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation the St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–1327.
    1. Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD. Development of a self-reported Chronic Respiratory Questionnaire (CRQSR) Thorax. 2001;56(12):954–959.
    1. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–415.
    1. Jones PW, Lasserson D. Relationship between change in the St. Georges Respiratory Questionnaire score and the patient’s perception of treatment efficacy after one years therapy with nedocromil sodium. Am J Respir Crit Care Med. 1994;149:A211.
    1. Jones PL. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398–404.
    1. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax. 2006;61:17–22.
    1. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD) Prim Care Respir J. 2007;16:236–240.
    1. Seemungal TAR, Cho Fook Lun J, Davis G, et al. Plasma homocysteine is elevated in COPD patients and is related to COPD severity. Int J Chron Obstruct Pulmon Dis. 2007;2(3):313–321.
    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:174757.
    1. Oliveira AF, Valente JG, Leite IC. The disease burden attributable to smoking in the state of Rio de Janeiro, Brazil in 2000. Clinics. 2008;63:215–222.
    1. Saha R, Nath A, Sharma N, Badhan SK, Ingle GK. Changing profile of disease contributing to mortality in a resettlement colony of Delhi. Natl Med J India. 2007;20:125–127.
    1. The Office of National Statistics of the United Kingdom Available at:
    1. The National Health Executive of the United Kingdom Available at: .
    1. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4:502–526.
    1. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the Economic Burden of COPD in the USA Review and Synthesis of the Literature. COPD. 2006;3:211–218.
    1. Nurmagambetov T, Atherly A, Williams S, Holguin F, Mannino DM, Redd SC. What is the cost to employers of direct medical care for chronic obstructive pulmonary disease. COPD. 2006;3:20–39.
    1. Traver GA. Measures of symptoms and life quality to predict emergent use of institutional health care resources in chronic obstructive airways disease. Heart Lung. 1998;17:689–697.
    1. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest. 2000;117:1S–5S.
    1. Calverley PM, Anderson JA, Celli B, et al. TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
    1. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction. Eur Respir J. 1988;1:22–26.
    1. Dompeling E, van Schayck CP, van Grunsven PM, van Herwaarden CL, Akkermans R, Molema J, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4 year prospective study. Ann Intern Med. 1993;118:770–778.
    1. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A metaanalysis. Ann Intern Med. 1991;114:216–223.
    1. Jan Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a metaanalysis. Thorax. 1999;54:7–14.
    1. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Longterm treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340:1948–1953.
    1. Spencer S, Calverley PMA, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:1–5.
    1. Calverley P, Pauwels R, Vestbo J, et al. TRial of Inhaled STeroids ANd longacting beta2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456.
    1. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:748–751.
    1. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–919.
    1. Global Initiative for Obstructive Lung Disease Update Available from .
    1. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1997;10:815–821.
    1. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957–965.
    1. Dahl R, Greefhorst LA, Nowak D, et al. Formoterol in Chronic Obstructive Pulmonary Disease I Study Group Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778–784.
    1. Rennard SI, Anderson W, ZuWallack R, et al. Use of a longacting inhaled beta2adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1087–1092.
    1. Salpeter SR, Buckley NS, Salpeter EE. Metaanalysis: anticholinergics, but not βagonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med. 2006;21:1011–1019.
    1. Gudmundsson G, Gislason T, Lindberg E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and comorbidity. Respir Res. 2006;7:109.
    1. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8:1398–1420.
    1. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med. 1984;311:421–425.
    1. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989;96:9847.
    1. Incorvaia C, RiarioSforza GG, Pravettoni C, Yacoub MR, Frati F. Impairment of small airways in COPD patients with frequent exacerbations and effects of treatment with tiotropium. Int J Chron Obstruct Pulmon Dis. 2008;3:123–126.
    1. Singh D. Tiotropium more knowledge leads to more questions. Int J Chron Obstruct Pulmon Dis. 2008;3:iii.
    1. Kawayama T, Hoshino T, Ichiki M, et al. Kurume COPD Study Group Effect of addon therapy of tiotropium in COPD treated with theophylline. Int J Chron Obstruct Pulmon Dis. 2008;3:137–147.
    1. Kesten S, Cassaburi R, Kukafka D, Cooper CB. Improvement in selfreported exercise participation with the combination of tiotropium and rehabilitative training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3:127–136.
    1. Johansson G, Lindberg A, Romberg K, Nordström L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J. 2008;17:169–175.
    1. Andò F, Ruggeri P, Girbino G, Cazzola M. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. Respir Med. 2008;102:815–818.
    1. Haag S, Matthiesen S, Juergens UR, Racké K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J. 2008;32:555–562.
    1. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A longterm evaluation of oncedaily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224.
    1. Vincken W, van Noord JA, Greefhorst AP, et al. Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19:209–216.
    1. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once daily inhaled anticholinergic bronchodilator. Ann Intern Med. 2005;143:317–326.
    1. Donohue JF, van Noord JA, Bateman ED, et al. A 6 month, placebocontrolled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47–55.
    1. Decramer M, Celli B, Tashkin DP, et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD. 2004;1:303–312.
    1. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554.
    1. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–555.
    1. Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592–598.
    1. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. Chest. 2008;134:255–262.
    1. Najafzadeh M, Marra CA, Sadatsafavi M, et al. CostEffectiveness of Therapy with Combinations of LongActing Bronchodilators and Inhaled Steroids for Treatment of COPD. Thorax. 2008;63:962–967.
    1. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low dose erythromycin. Am J Respir Cri Care Med. 1998;157:1829–1832.
    1. Takeda H, Miura H, Kawahira M, et al. Longterm administration study on TE031 (A56268) in the treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi. 1989;63:71–78.
    1. Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Longterm therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi. 1990;28:1305–1313.
    1. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis:a randomized trial. Thorax. 2002;57:21–26.
    1. Equi A, BalfourLynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis:a randomised, placebocontrolled crossover trial. Lancet. 2002;360:978–984.
    1. Saiman L, Marshall BC, MayerHamblett N, et al. Macrolide Study Group Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749–1756.
    1. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled Trial. Thorax. 2006;61:895–902.
    1. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and Common Cold in COPD. Chest 120. 2001:730–733.
    1. Seemungal T, Wilkinson TMA, Hurst JR, Perera W, Sapsford RJ, Wedzicha JA. Long term macrolide therapy is associated with decreased COPD exacerbation frequency. Am J Respir Crit Care Med. 2008;178:1139–1147.
    1. Rossi A, Kristufek P, Levine BE, et al. Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group Comparison of the efficacy, tolerability and safety of formoterol dry powder and oral slow-release theophylline in treatment of COPD. Chest. 2002;121:1058–1069.
    1. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006;11:603–610.
    1. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6 month, placebocontrolled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006;129:56–66.
    1. Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006;533:110–117.
    1. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and out patient visits, hospitalisation and mortality in elderly patients with chronic lung disease. Ann Intern Med. 1999;130:397–403.
    1. Granger R, Walters J, Poole PJ, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(4):CD001390.
    1. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax. 2006;61:189–195.
    1. Collet JP, Ducruet T, Haider S, et al. Effect of an immunostimulating agent on acute exacerbations and hospitalization in COPD patients. Am J Respir Crit Care Med. 1997;156:1719–1724.
    1. Sprenkle MD, Niewoehner DE, MacDonald R, Rutks I, Wilt TJ. Clinical efficacy of OM85 BV in COPD and chronic bronchitis:a systematic review. COPD. 2005;2:167–175.
    1. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001;322:127–174. [Updated at Cochrane Database Syst Rev 2006 Jul 19;3:CD001287]
    1. Decramer M, Ruttenvan Mölken M, Dekhuijzen PN, et al. Effects of Nacetyl cysteine on outcomes in COPD (BRONCHUS trial) Lancet. 2005;365:155–260.
    1. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebocontrolled study. Lancet. 2008;371:2013–2018.
    1. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation. Lancet. 2000;355:362–68.
    1. Boxall AM, Barclay L, Sayers A, Caplan GA. Managing chronic obstructive pulmonary disease in the community. A randomized controlled trial of homebased pulmonary rehabilitation for elderly housebound patients. J Cardiopulm Rehabil. 2005;25:378–385.
    1. Foglio K, Bianchi L, Ambrosino N. Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2 year controlled study. Chest. 2001;119:1696–1704.
    1. Ringbaek TJ, Brøndum E, Bolton S, Martinez G, Lange P. [Rehabilitation of patients with chronic obstructive pulmonary disease. Effect of a 7 week programme after 12 months] Ugeskr Laeger. 2007;169:1572–1576.
    1. Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality a systematic review. Respir Res. 2005;6:54.
    1. Foglio K, Bianchi L, Bruletti G, et al. Seven year time course of lung function, symptoms, healthrelated quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. Respir Med. 2007;101:1961–1970.
    1. Di Meo F, Pedone C, Lubich S, Pizzoli C, Traballesi M, Incalzi RA. Age does not hamper the response to pulmonary rehabilitation of COPD patients. Age Ageing. 2008;37:530–535.
    1. GarciaAymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM, for the Estudi del Factors de Risc d’Agudització de la MPOC investigators Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003;58:100–105.
    1. GarciaAymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61:772–778.
    1. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Noninvasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease:Cochrane systematic review and metaanalysis. BMJ. 2003;326:185.
    1. Tuggey JM, Plant PK, Elliott MW. Domiciliary noninvasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis. Thorax. 2003;58:867–871.
    1. Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J. 2002;20:529–538.
    1. Budweiser S, Hitzl AP, Jörres RA, et al. Impact of noninvasive home ventilation on longterm survival in chronic hypercapnic COPD: a prospective observational study. Int J Clin Pract. 2007;61:1516–1522.
    1. Xiang PC, Zhang X, Yang JN, et al. The efficacy and safety of long term home noninvasive positive pressure ventilation in patients with stable severe chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2007;30:746–750.
    1. Wedzicha JA. Outcome of longterm noninvasive positivepressure ventilation. Respir Care Clin N Am. 2002;8:559–573.
    1. Nocturnal Oxygen Therapy Trial Group (NOTT) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease:a clinical trial. Ann Intern Med. 1980;93:391–398.
    1. Medical Research Council Working Party (MRC) Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet. 1981;1:178. 681–686.
    1. Kim V, Benditt JO, Wise RA, Sharafkhaneh A. Oxygen therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:513–518.
    1. Chaouat A, Weitzenblum E, Kessler R, et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J. 1999;14:1002–1008.
    1. Tanni SE, Vale SA, Lopes PS, Guiotoko MM, Godoy I, Godoy I. Influence of the oxygen delivery system on the quality of life of patients with chronic hypoxemia. J Bras Pneumol. 2007;33:161–167.
    1. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101:1398–1405.
    1. Blais L, Bourbeau J, Sheehy O, LeLorier J. Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. Can Respir J. 2004;11:27–32.
    1. Ferguson GT, FunckBrentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest. 2003;123:1817–1824.
    1. Rodrigo GJ, Nannini LJ, RodríguezRoisin R. Safety of longacting betaagonists in stable COPD: a systematic review. Chest. 2008;133:107987.
    1. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006;61:854–862. Erratum in: Thorax. 2006;62:191.
    1. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and metaanalysis. JAMA. 2008;300:1439–1450.
    1. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease:a systematic review of randomized placebocontrolled trials. Am J Med. 2002;113:59–65.
    1. Garbe E, Suissa S, LeLorier Association of inhaled corticosteroid use with cataract extraction in elderly patents. JAMA. 1998;280:539–543.
    1. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8–14.
    1. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bonemineral density in patients with asthma. Lancet. 2000;355:1399–1403.
    1. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and metaanalysis. Arch Intern Med. 1999;159:941–955.
    1. Goldkorn A, Diotto P, Burgess C, et al. The pulmonary and extrapulmonary effects of highdose formoterol in COPD: a comparison with salbutamol. Respirology. 2004;9:102–108.
    1. Rosenkranz B, Rouzier R, Kruse M, et al. Safety and tolerability of highdose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. Respir Med. 2006;100:666–672.
    1. Campbell SC, Criner GJ, Levine BE, et al. Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2007;20:571–579.
    1. Sheth K, Wasserman RL, Lincourt WR, Locantore NW, CarranzaRosenzweig J, Crim C. Fluticasone propionate/salmeterol hydrofluoroalkane via metereddose inhaler with integrated dose counter: Performance and patient satisfaction. Int J Clin Pract. 2006;60:1218–1224.
    1. Lavorini F, Magnan A, Dubus JC, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593–604.
    1. Janssens W, VandenBrande P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;31:78–83.
    1. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for reevaluation? Age Ageing. 2007;36(2):21–38.
    1. AlShowair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help. Respir Med. 2007;101:2395–2401.
    1. Barta SK, Crawford A, Roberts CM. Survey of patients’ views of domiciliary nebuliser treatment for chronic lung disease. Respir Med. 2002;96:375–381.
    1. Seemungal TAR, Wedzicha JA. Integrated care: a new model for COPD management? Eur Respir J. 2006;28:13.
    1. van Campen C, Sixma HJ, Kerssens JJ, Peters L. Assessing noninstitutionalized asthma and COPD patients’ priorities and perceptions of quality of health care. J Asthma. 1997;34:531–538.
    1. Sixma HJ, van Campen C, Kerssens JJ, Peters L. Quality of care from the perspective of elderly people: the QUOTEelderly instrument. Age Ageing. 2000;29:17–38.
    1. Bourbeau J, Julien M, Maltais F, et al. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. 2003. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific selfmanagement intervention. Arch Intern Med. 2003;163:585–591.
    1. Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2008;63:194–200.
    1. Taylor SJ, Candy B, Bryar RM, et al. Effectiveness of nursing and nurse led chronic disease management innovations for patients with chronic obstructive pulmonary disease: systematic review of evidence. BMJ. 2005;2005;331:485.
    1. Casas A, Troosters T, GarciaAymerich J, et al. members of the CHRONIC Project. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J. 2006;28:123–130.
    1. GarciaAymerich J, Hernandez C, Alonso A, et al. Effects of an integrated care intervention on risk factors of COPD readmission. Respir Med. 2007;101:1462–1469.
    1. Monninkhof E, van der Valk P, Schermer T, van der Palen J, van Herwaarden C, Zielhuis G. Economic evaluation of a comprehensive selfmanagement programme in patients with moderate to severe chronic obstructive disease. Chron Respir Dis. 2004;1:7–16.
    1. Steuten L, Vrijhoef B, Van Merode F, Wesseling GJ, Spreeuwenberg C. Evaluation of a regional disease management programme for patients with asthma or chronic obstructive pulmonary disease. Int J Qual Health Care. 2006;18:429–436.
    1. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(4):CD003793.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever